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ABSTRACT 
Sphingolipid imbalance is the culprit in a variety of neurological diseases, some 
affecting the myelin sheath. We have used whole exome sequencing in patients with 
undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid 
desaturase DEGS1 as the causative gene in nineteen patients from thirteen unrelated 
families. Shared features among the cases include severe motor arrest, early nystagmus, 
dystonia, spasticity and profound failure to thrive. MRI showed hypomyelination, 
thinning of corpus callosum and progressive thalami and cerebellar atrophy, suggesting 
a critical role of DEGS1 in myelin development and maintenance. This enzyme 
converts dihydroceramide (DhCer) into ceramide (Cer) in the final step of the de novo 
biosynthesis pathway. We detected a marked increase of the substrate DhCer and 
DhCer/Cer ratios in patient’s fibroblasts and muscle. Further, we used a knockdown 
approach for disease modelling in Danio rerio, followed by a preclinical test with the 
first-line treatment for multiple sclerosis, fingolimod (FTY720, Gilenya). The 
enzymatic inhibition of ceramide synthase, one step prior to DEGS1 in the pathway, by 
fingolimod, reduced the critical DhCer/Cer imbalance and the severe locomotor 
disability, increasing the number of myelinating oligodendrocytes in the zebrafish 
model. These proof-of-concept results pave the way to clinical translation.  
Keywords 
DEGS1; Hypomyelinating Leukodystrophy; Sphingolipids; Ceramides; Fingolimod 
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Introduction 
Leukodystrophies (LD) are a heterogeneous group of rare, heritable disorders of 
all ages that primarily affect the brain’s white matter, often leading to motor and 
cognitive impairment in early childhood and progression to severe disability over time 
(1, 2). All modes of inheritance, broad pathogenic mechanisms, and complex cellular 
interactions underlie LD, yet many cases remain unexplained with an unknown 
biochemical or molecular basis (3). With progress in clinical genomics, new forms of 
ultra-rare leukodystrophies are being recognized (4-6), and advances in novel 
technologies in gene, cell and enzyme therapy hold promise for improving patient 
management (7, 8).  
Using whole exome sequencing (WES), we have identified homozygous or 
compound heterozygous pathogenic variants in the DEGS1 gene in nineteen 
leukodystrophy patients from thirteen unrelated families. DEGS1 was first cloned in 
1996 from Drosophila melanogaster, and was given the name ‘‘drosophila degenerative 
spermatocyte 1” or DEGS1 (9). It encodes a Δ4-dihydroceramide desaturase (OMIM 
615843) mapping to chromosome 1q42.11, also known as DES1. This enzyme catalyzes 
the insertion of a Δ 4,5-trans double bond into dihydroceramide (DhCer) to convert it to 
ceramide (Cer), in the final step of the de novo ceramide biosynthesis pathway (Figure 
1) (10).  
Biosynthesis of Cer, made of a sphingoid base and a fatty acid, mainly occurs 
via three distinct pathways: a) the de novo pathway, which takes place in the 
endoplasmic reticulum (ER) and uses palmitoyl-CoA and serine as its precursors; b) the 
sphingomyelinase pathway, which takes place in the plasma membrane, Golgi apparatus 
and mitochondria, and converts sphingomyelin into Cer bi-directionally; and c) the 
salvage pathway, which converts complex sphingolipids species into Cer and recycles 
the acyl moiety of ceramides in both lysosomes and endosomes (Figure 1) (11). This 
compartimentalization of the more than 200 structurally distinct ceramides suggests a 
high complexity of regulation and function, which is only beginning to emerge (12, 13). 
Cer is the central unit of all sphingolipids, serving as a building block and as a 
hub for bioactive, more complex lipidic species. The biosynthesis of Cer is followed by 
the addition of sugar moieties to generate glucosylceramide and galactosylceramide, 
which undergo further transformation into gangliosides and sulfatides, respectively. 
Galactosylceramides and sulfatides with very long N-acyl chains, in particular C24:0 
and C24:1, are the most abundant myelin lipid components (14, 15). Indeed, defects of 
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galactosylceramidase and arylsulfatase A, one and two steps after DEGS1 respectively, 
cause Krabbe disease/globoid leukodystrophy (GLD) and metachromatic 
leukodystrophy (MLD) (Figure 1), two well-characterized demyelinating LD. Beyond 
the myelin sheath, sphingolipids are involved in numerous biological processes related 
to cell survival, metabolic regulation and adaptation to stressors (16). The importance of 
sphingolipids in neurodegenerative disease has recently expanded beyond lysosomal 
disorders or classical sphingolipidosis. Secondary disturbances of these lipid species 
including DhCer have been shown in Huntington disease (17) and Alzheimer’s patients 
(18). 
Evidence from studies in animal models supports an essential role of DEGS1 in 
development (19, 20). Homozygous Degs1-/- mice die within the first 8 weeks of age, 
presenting a complex phenotype, including small size, scaly skin, sparse hair and 
tremors (19). Lipidomics analysis showed that Degs1-/- mice exhibit accumulation of 
DhCer and higher DhCer/Cer ratio in several tissues (19), similarly to the Drosophila 
melanogaster model (20).  
Our patients presented with hypomyelinating LD with progressive atrophy of 
corpus callosum (CC), thalami and cerebellum, severe failure to thrive and peripheral 
neuropathy. Using patients’ fibroblasts, we functionally validated variants by testing 
their impact on DhCer/Cer ratios and reactive oxygen species (ROS) production. 
Importantly, treatment with fingolimod (FTY720), a drug targeting sphingolipid 
metabolism and broadly used treatment for relapsing-remitting multiple sclerosis (MS), 
improved the metabolic imbalance, numbers of myelin-producing oligodendrocytes and 
locomotor deficits in the zebrafish model.  
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Results 
 
Bi-allelic deleterious variants of DEGS1 in patients with brain white matter 
abnormalities 
As part of our ongoing studies on the molecular basis underlying undiagnosed 
leukoencephalopathies, we identified a total of 19 individuals from 13 unrelated 
families with rare variants suspected to alter DEGS1 function (Figure 2; Table 1-2). The 
first patient under investigation was a female who presented feeding difficulties since 
birth, extreme irritability, hypertonia with opisthotonus, and nystagmus, resulting in 
death at 18 months. Severe hypomyelination was observed in the central and peripheral 
nervous system in the MRI and nerve conduction studies (Individual 6, Table 1-3). 
Extensive diagnostic investigations were negative. We thus carried out WES (see 
Experimental Procedures) in the proband, with subsequent Sanger validation and 
segregation analysis (Supplementary Figure 1). We identified an homozygous 
frameshift variant in DEGS1 (GenBank ID: NM_003676.3, c.604delT; 
p.(Tyr202Thrfs*8)) that was not present in the genome aggregation database 
(GnomAD; >246,000 chromosomes), the NHLBI Exome Variant Server (EVS; >13,000 
alleles), or the Exome Aggregation Consortium (ExAC) database (ExAC> 60.706 
individuals). No homozygous loss-of-function (LoF) variants were present for this gene 
in the mentioned databases. Personal communication with international Reference 
Centers for Leukodystrophies and information exchange on the GeneMatcher (21) 
platform facilitated the identification of 18 additional affected individuals with DEGS1 
variants from various ethnical backgrounds who displayed overlapping phenotypes. 
These variants were present in a homozygous or compound heterozygous manner in 
thirteen families and segregated in the recessive inheritance mode. Consanguinity was 
present in 2/3 of the families. All consanguineous families harbor a homozygous variant 
except family 9. 
DEGS1 encodes an evolutionary conserved sphingolipid desaturase of 323 AA 
containing six transmembrane domains, three histidine motifs, a lipid desaturase domain 
and a fatty acid desaturase (FAD) domain (Figure 2). The highly-conserved histidine 
motifs HX(3–4)H, HX(2–3)HH, and H/QX(2–3)HH, are essential for catalytic activity (10). 
Twelve out of thirteen variants are located in the FAD domain, and only one, 
p.(Met37Thr), is located in the sphingolipid delta4-desaturase domain. The most 
prevalent DEGS1 variants in our cohort were p.(Asn255Ser) and p.(Trp107*), identified 
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in three and two independent families, respectively. Eight out of thirteen variants have 
not been identified in control populations, and the rest of the variants have a MAF lower 
than 0.0001, with none being found in the homozygous state in the ExAC, GnomAD, 
1000 Genomes, Iranome or GME Variome databases. Seven out of thirteen variants are 
nonsense with four stopgain and three frameshifts. Six out of thirteen variants are 
missenses with high deleteriousness predicted by most of the 15 in silico tools tested 
(Supplementary Table S1).  
 
Clinical features  
Among the 19 affected patients, age of onset was at 5.6 months (+/- 7.2 m; 0.5-
24 months) with variable disease severity. Fifteen of the patients (79 %) presented a 
severe form characterized by a very poor psychomotor development, dystonia and 
severe spasticity (Table 1-2 and Supplementary Video). All except one subject 
presented early nystagmus or abnormal eye movements between 1 and 6 months of age. 
Seizures were frequently observed (80%) around 2 years of age with a pharmaco-
resistant epilepsy sensitive to ketogenic diet in only 3 cases. In this group, failure to 
thrive was the most worrying clinical issue after 2 years of age despite feeding through 
gastrostomia. Head circumference was relatively conserved with acquired microcephaly 
(< 2 DS) in only 3 cases. Death occurred in 4 patients (26%) at a mean age of 4.6 years 
(+/-1.9; 2.5-7 y). These 4 patients harbored LoF variants (Table 1-2). 
In the remaining 22% of the patients) (patients 3, 7, 8, 14), a less severe 
phenotype was observed. Acquisition was better with capacity to sit or walking and to 
use a verbal communication. Progressive spasticity developed rapidly in these patients 
leading to motor degradation at various ages (2 to 16y). None presented with growth 
impairment (<2SD) or microcephaly (Table 1-2).   
Cerebral MRI images were available for review by expert clinicians (AF, SAA, 
CC, DR, OBT) for 18 patients at mean age 3.6 y (+/-4.2; 0.5-17 y) (Table 3). All 
patients showed T2/FLAIR hyperintense white matter lesions with a normal 
hyperintense T1 indicative of an hypomyelinating form of LD (Figure 3 and 
Supplementary Figure 2) (22). In the 3 mildest clinical forms of the disease (patients 7, 
8, 14), the abnormal WM signal affected the deep white matter with a relative 
preservation of the subcortical regions (Figure 3A, patient 7). In two severe cases a 
demyelinating aspect of the posterior subcortical-deep WM was noticed on T1 
(Supplementary Figure 2, patients 4 and 10). Despite the severity of the clinical 
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symptoms, myelination progressed in the 6 patients analyzed with 2 or more MRI and a 
mean follow up of 4.2 y (+/-3.5 y; 1-10 y) (Figure 3B and Supplementary Figure 2).  
Basal ganglia abnormalities were observed in only the most severe forms. 
Abnormal hyper T2/FLAIR signal and atrophy of the thalami were the most frequent 
findings (11/15 cases, 73%) (Figure 3, Table 3, Supplementary Figure 2). Two severe 
patients (patient 2 and 19) showed an associated hypoT2/FLAIR in the pallidi (Table 3). 
Thinning of the CC was observed in 76 % of cases associated with progressive 
vermian cerebellar atrophy in 41% of cases (Figure 3, Supplementary Figure 2). 
Demyelinating neuropathy with nerve conduction below 35m/s was observed in 5 out of 
the 14 patients analyzed by EMG /NCV (1/3). The evoked potentials performed in 7 
patients (4 BAEP; 5 VEP; 1 SEP) demonstrated long latencies in the central conduction 
(> 3 SD) in all cases (Table 1-2). 
 
Genotype-phenotype correlation 
Patients from the same families (Table 1-2, see families 1, 3, 5, 8, 10) as well as 
patients with the same genotype (Table 1-2, see Algerian families 6 and 7; Egyptian 
families 8 and 12), expressed the same phenotype. Patients 2, 6, 11 and 12 who 
harbored homozygous LoF variants in the FAD domain, died at 7 years, 18 months, 2.5 
and 5 years of age respectively, indicating a likely phenotype-genotype correlation. At 
the other end of the spectrum we found patient 3, a 9-year-old girl with p.(Arg133Trp) 
and p.(Leu251Phefs*10) variants in trans, who presented with developmental 
regression from 9 months of age; however she was able to sit without help and 
communicate using simple sentences. Her MRI and spectroscopy were almost normal at 
4 and 5 years of age and presented no signs of peripheral neuropathy.  
 
DEGS1 activity is impaired in patients’ fibroblasts and muscle  
To verify the impact of the variants on DEGS1 protein function, we used 
targeted lipidomics to quantify dihydroceramides and ceramides, the substrates and 
products of DEGS1 respectively. The results indicate a slight reduction of ceramides  
(Cer) concomitant with an important accumulation (3 to 9 fold) of dihydroceramides 
(DhCer) in cultured skin fibroblasts of affected individuals (patients 4, 7, 9) and muscle 
tissue (patient 3). Thus, the activity of the DEGS1 enzyme, represented as the 
DhCer/Cer ratio, was greatly decreased in all cases (Figure 4A-B), consistent with the 
notion that the variants identified caused reduced activity of the DEGS1 enzyme. 
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Impaired function of DEGS1 induces intracellular ROS production  
Excess of dihydroceramides has been recently reported to generate ROS in 
Drosophila ifc KO photoreceptors (20). We observed that ROS production was 
increased in all patients’ fibroblasts (patients 4, 7 and 9) compared to controls (Figure 
4C), using the probe H2DCFDA which measures singlet oxygen, superoxide, hydroxyl 
radical and various peroxides and hydroperoxides (23). To gain insight into the direct 
consequences of DhCer accumulation in our system, we incubated control and patients 
fibroblasts with a long-chain DhCer (C18:0-DhCer) for 6h, at a dose of 20 µM. This 
dose increased ROS production in control fibroblasts although we could not discern an 
increase in the patient fibroblasts (Figure 4D). At higher doses, we found toxic effects 
in the fibroblasts independent of phenotype. This result confirmed that DhCer excess 
can generate ROS in human fibroblasts, whereas the blunted response in patient 
fibroblasts may follow saturation effects due to the steady-state accumulation of DhCer.  
 
Degs1 is highly expressed in the central nervous system (CNS) 
We performed RT-qPCR expression studies in different child and adult control 
human CNS tissues (n=2), to find specific expression of this gene in frontal lobe BA9, 
putamen, entorhinal cortex, hippocampus, hypothalamus, pons, cerebellum, white 
matter frontal cortex, spinal cord (Supplementary Figure 3A). This is consistent with the 
expression of Degs1 mRNA in different tissues of 4 month old wild type mice (n=3), 
with high expression in the CNS, in particular in spinal cord, brain cortex, pons, 
cerebellum and hippocampus, compared to other organs (Supplementary Figure 3B). 
We next performed RT-qPCR to assess the DEGS1 mRNA expression in fibroblasts 
from affected individuals (patients 4, 7 and 9) and healthy age-matched control 
individuals. We observed a 50% decrease in patient 4 (Supplementary Figure 3C), 
possibly owing to mRNA decay in the allele bearing the stop variant. We also analyzed 
the expression of DEGS2, the closest paralog of DEGS1, which is reported to have a 
partially overlapping, low C4-desaturase activity while showing a high C4-hydroxylase 
activities (24, 25). We corroborated a high expression of DEGS2 in small intestine and 
kidney (24), comparable to DEGS1 (Supplementary Figure 3B), and two orders of 
magnitude lower expression in mouse brain and human fibroblasts as compared to 
DEGS1, which argues against any putative, physiologically relevant compensatory role 
of DEGS2 (Supplementary Figure 3B-C). 
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Loss of Degs1 in zebrafish causes DhCer/Cer imbalance, reduced number of 
oligodendrocytes and locomotor impairment  
We investigated the suitability of a zebrafish model for this disease, since many 
of the genetic pathways for myelin development and maintenance are conserved (26). 
There is a single zebrafish ortholog of human DEGS1 (NP_997865.1), sharing a 74% 
protein identity with human DEGS1 (NP_003667.1). In situ hybridization (ISH) studies 
showed that Degs1 was expressed in the dorsal part of the zebrafish brain, being more 
prominent in the dorsal thalamus, the posterior tuberculum, the tectum opticum, the 
hindbrain and the spinal cord (Supplementary Figure 4A-B). Using a transgenic strain 
expressing EGFP under the control of the myelin basic protein (mbp) promoter labeling 
myelinating oligodendrocytes (MBP+) (27), we found overlapping pattern of Degs1 to 
MBP+ cells (Supplementary Figure 4C-F). Thus, we knocked down Degs1 in zebrafish, 
by designing an efficient splice-blocking morpholino (MO) (Supplementary Figure 4G-
I). Downregulation of DEGS1 induced an increase of DhCer and of the DhCer/ Cer 
ratio (Figure 5A) at 5 days post-fertilization (5 dpf). Moreover, a high percentage of 
MO-DEGS1 larvae displayed an abnormal morphology (Figure 5B-C). 
Next, phenotype and swimming ability of MO-DEGS1 zebrafish larvae was 
analyzed by measuring the total movement distance and by comparing the activity 
displayed by uninjected, and MO-control injected larvae. The total movement distance 
(mm) in MO- DEGS1 larvae was very significantly reduced (Figure 5D-E). Importantly, 
when embryos were injected with 10 ng of MO-DEGS1, no significant differences were 
observed in the survival rate compared to embryos injected with MO-controls or 
uninjected animals. To test the effect on myelination of the knockdown of DEGS1 in 
zebrafish, we measured the number of MBP+ cells in the spinal cord at 4·5 dpf after 
MO-DEGS1 injection (27). Interestingly, we found that the number of MBP+ cells was 
reduced by 30 % in MO-DEGS1 compared to control larvae (Figure 5F-G’). Altogether, 
these results indicate that loss of DEGS1 function in zebrafish larvae results in some 
ten- fold increased DhCer/Cer ratio, locomotor disability and impaired myelination, 
consistent with the patients’ phenotype.  
 
FTY720 ameliorates in the phenotype of MO-DEGS1 zebrafish, while reducing 
ROS levels in patient fibroblasts 
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Drug screening in zebrafish has been successfully used to identify target pathways as 
well as therapeutic compounds for human diseases (28). In an attempt to provide a 
therapeutic option for this life-threatening condition, we chose an FDA-approved drug 
targeting the de novo ceramide biosynthesis pathway, fingolimod (FTY720). This 
pleiotropic drug is reported to act as an inhibitor of the enzyme prior to DEGS1, the 
ceramide synthase (CerS) (Figure 1) (29). We used concentrations of 3·3, 1·0 and 0·3 
ng/µl of FTY720, from birth to 120 hpf, without observing deleterious effects on 
survival. Also the number of MBP+ signals along the spinal cord was raised in MO-
DEGS1 larvae after treatment, approaching the number of MBP+ cells in control larvae 
(Figure 5F-J). The locomotor deficit of MO-DEGS1 larvae was remarkably ameliorated 
after 5 days of treatment with FTY720 at 1·0 ng/µl (Figure 6A-B). This recovery 
correlated with an amelioration of total DhCer levels and ratios of DhCer/Cer upon 
treatment (Figure 6C). The effect of the drug was more marked towards some DhCer 
species (the saturated and monounsaturated C16- ,C17-, C18-, C20-, C22-, C24-, C26-, 
C28-DhCer ), which also accumulated the most. Of note, a ten fold decrease of C10-Cer 
was also observed, and recovered with treatment (Supplemental Table S2). Next, we 
tested a potential protective effect of FTY720 on ROS generation in DEGS1-fibroblasts 
(patients 4, 7 and 9 as above), by using a dose of 5 M for 6 h and measuring the ROS 
levels as described above. FTY720 treatment prevented the elevation of ROS levels in 
patient fibroblasts (Figure 6D), while no effect was seen in control fibroblasts. These 
results provide proof of principle that FTY720 reduces the accumulation of DhCer and, 
thus, results in diminished ROS production at the cellular level.  
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Discussion 
This study highlights the interest of using freely accessible information 
exchange platforms such as GeneMatcher after exome sequencing, for rapid 
identification of molecular causes of ultrarare disorders and collection of sufficient 
cases to delineate a disease spectrum and improve management (30).  
Patients with DEGS1-related LD shared clinical and MRI features of 
hypomyelinating LD. In this heterogeneous group of LD, a large clinical spectrum of 
disease severity has been described in terms of defective myelination and axonal 
suffering. A large majority of our DEGS1 patients present the severe form of 
hypomyelinating LD, accompanied by thin CC and cerebellar atrophy as observed with 
TUBB4-related LD (31). However, the hypomyelination observed in TUBB4, as well as 
in the severe forms of PLP1-related LD, is more diffuse and remains stable over time 
(32). The relative preservation of the subcortical white matter relative to the clinical 
severity of DEGS1-patients may represent an interesting MRI diagnostic feature. 
Likewise, the observed improvement in myelination in our patients contrasts with the 
progressive atrophy affecting first the CC, then thalami and cerebellum, and finally the 
whole brain. This suggests a critical role of DEGS1 and ceramide metabolism in myelin 
development and maintenance, but also in neuronal/ axonal functioning. The 
hypomyelinating pattern of the deep WM and the T2 hyperintensities of the thalamic 
regions are also observed in infantile GM1/GM2 gangliosidosis (22, 33). Finally, the 
association of central and peripheral demyelination are the hallmarks of disorders of 
sphingolipid metabolism (MLD and GLD), and of the peroxisomes (34). Although 
individual features in the DEGS1-related patients are not specific, their combination 
results in a defined pattern distinguishable from other LD. 
The importance of maintaining sphingolipid balance for the nervous system is 
well exemplified in the lysosomal disorders such as Gaucher, Niemann Pick or Farber, 
all one enzymatic step away from DEGS1 (Figure 1) (8). Indeed, in many lipid storage 
disorders, deficiency or malfunctioning of one of the enzymes involved in sphingolipid 
metabolism results in accumulation of the corresponding lipid substrate leading to 
cellular dysfunction and death. Accumulation of DhCer is involved in many stress 
signals such as cell cycle regulation, autophagy induction, apoptosis and ROS 
generation (35, 36); the latter being substantiated by our results. Redox imbalance is 
intertwined with energy homeostasis in diseases of myelin (23, 37), and may play a role 
in the cachexia observed, in the large majority of our patients. Moreover, suppressing 
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DEGS1 led to cell cycle arrest, cell growth inhibition and apoptosis in cell culture 
models (16, 38), which may explain the decrease of myelinating MBP+ oligodendrocyte 
numbers and perhaps contribute to the general developmental delay and impressive 
failure to thrive in our patients. Concerning the biogenesis and stability of the myelin 
sheath, an enhanced proportion of DhCer (in particular C16-DhCer) has recently been 
shown to destabilize model membranes by increasing permeability and the formation of 
rigid domains (35). Of note, C16-DhCer is increased in our MO-DEGS1 model and 
lowered by fingolimod treatment (Supplementary Table S2). It is therefore tempting to 
posit that the exquisitely regulated process of myelin sheath biogenesis and compaction, 
including the lipid-lipid and lipid-protein interactions with major protein players such as 
MBP, MAG or PLP (14, 39).) is likely to be severely disturbed, simply by the 
biophysical consequences of the DhCer/Cer imbalance on the cellular membranes.  
 Further, it has been recently shown that in the Drosophila (ifc) KO, 
photoreceptor degeneration was caused by increased DhCer, not reduced levels of Cer 
(20). Along the same lines, Cer reduction by itself appears to have a positive effect by 
enhancing myelin repair in acute and chronic demyelination paradigms, as deduced 
from a model of acid sphingomyelinase deficiency (40). Of note, impairment of the 
alkaline ceramidase 3 (ACER3), just one step after DEGS1 (Figure 1), causes a recently 
described form of childhood leukoencephalopathy of similar clinical presentation to the 
DEGS1-related LD, with an hypomyelinating aspect of the periventricular and deep 
WM, severe brain atrophy by 5 years of age, and peripheral neuropathy (5). It is 
intriguing that the plasma profile of the described patient showed mainly accumulation 
of DhCer, along with various Cer forms and lactosylceramides in lesser extent (5). 
Further investigations will be necessary to determine the precise molecular mechanisms 
through which excess of DhCer, may be toxic for myelinating oligodendrocytes or for 
the biogenesis of the myelin sheath. By the same token, and beyond the plausible direct 
negative effects of substrate accumulation in this case, we should acknowledge that 
sphingolipid metabolism constitutes an intricate network coupled in a “metabolic 
ripple” (16). As such, the loss of a given enzyme function may cause a shift in the 
substrate specificity of other enzymes in the pathway, leading to increased production of 
atypical lipid products that may be toxic to the cell (41). This intriguing possibility 
should be explored for DEGS1, likely by using a systems biology-type of approach, 
ideally including integration of comprehensive lipidomics and transcriptomics data (42). 
A bulk of evidence suggests that fingolimod has potential to become a lead player in 
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this context. Its success in relapsing-remitting MS relies on its activity as 
immunosuppressant, acting by sequestering circulating mature lymphocytes to the 
lymph nodes, and preventing their penetration into the brain and subsequent myelin 
destruction. Its molecular effects promoting neuron and oligodendrocytes survival are 
based on the structural similarity of FTY720 to sphingosine, which allows it to work as 
a bona-fide functional antagonist to S1P receptors (43, 44), and has lately shown to 
even improve microstructural integrity and myelination in the white matter tracts of 
human MS patients (45).  
In part because of this structural similarity to sphingosine, FTY720 is a 
pleiotropic drug that also interferes with sphingolipid de novo biosynthesis, mainly by 
inhibiting ceramide synthase (CerS) (29, 43), the enzyme that converts sphinganine to 
DhCer, one step prior to DEGS1, and also converts sphingosine to ceramide (Figure 1). 
There are six CerS orthologs in mammals (46) and nine –due to whole genome 
duplication- in zebrafish (47). These enzymes transfer a variable length fatty acyl-
coenzyme A (CoA) to the amine group of sphinganine or sphingosine. Studies 
employing genetic manipulations have demonstrated that different CerS isoforms 
exhibit strong preference for fatty acyl-CoAs with differing carbon chain lengths, 
although with extensive overlaps. CerS1 exclusively uses 18 carbon (C18) fatty acids, 
forming C18 (d18:1/18:0) ceramide, whilst CerS2 preferentially forms 
d18:1/24:0(C24:0) and d18:1/24:1 (C24:1) ceramides. CerS3 synthesizes very long 
chain ceramides (>C26-Cer), CerS4 forms C18-/C20-/C24-Cer; CerS5 and CerS6 
synthesize mostly C14-/C16-/C18-Cer (48, 49). Thus, the broad spectrum of DhCer 
species accumulated first in the DEGS1 zebrafish model, and then reduced by 
fingolimod (spanning C13:1 DhCer to C28:0 DhCer, Supplemental Table 2), adds 
complexity to future studies aiming to identify the drug’s most plausible targets in this 
model.  
Additional experimental evidence supports the protective effect of FTY720 in 
sphingolipid metabolism-related disorders, such as GLD, which is caused by 
inactivation of galactosylceramidase (GALC) resulting in the accumulation of the toxic 
metabolite galactosylsphingosine (psychosine) in the brain. FTY720 treatment 
attenuated the psychosine-induced demyelination process in mouse organotypic 
cerebellar slice cultures (50). With this notion in mind, and our proof-of-principle 
results in a model organism, we posit that FTY720 (or novel, more specific next-
generation sphingosine analogs interfering with CerS or other enzymatic steps along the 
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pathway may provide a promising therapeutic option for white matter disorders linked 
to DEGS1 deficiency and perhaps others in sphingolipid metabolism, paving the way 
for the repurposing of FTY720 for other diseases. Our next step as a DEGS1-
consortium is the validation of a robust biomarker in plasma (such as DhCer/Cer ratios) 
to monitor target engagement upon treatment and to prepare for early clinical 
intervention aiming to alleviate and modify disease course of this life-threatening 
condition.  
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Materials and methods 
Patients, Genetic Studies and Ethics Statement 
All 19 affected individuals underwent extensive clinical examination by a pediatric 
neurologist and at least one expert clinical geneticist at their referral hospitals, where 
broad metabolic and genetic testing was performed. Standardized phenotypic data were 
collected by review of the clinical histories and follow-up investigations (See Table 1-
3). All available clinical and magnetic resonance image (MRI) data were collected and 
jointly reviewed. Whole-exome sequencing (WES) on an Illumina HiSeq platform were 
performed according to the following paradigms: (1) trio-based clinical diagnostic WES 
(individuals 1, 7, 9, 10, 11, 14, 17), (2) trio-based WES or trio-based WES plus affected 
sibling in a research-based analysis (individuals 3, 4, 15, 18, 19 ), or (3) WES of an 
affected individual followed by single site testing in parental DNA samples (individuals 
6 and 8). Point mutations and indels were confirmed by Sanger sequencing of DNA 
sample from all available family members, when possible (Supplementary Table 3). The 
exome sequences have been deposited in public repositories: Patients 4 
(phs000711.v5.p1), patients 13 (phs000744.v4.p2), and 18 (phs001272.v1.p1) into 
dbGaP; patient 1 (P0007232), patient 6 (P0005949), patient 7 (P0007704), patient 8 
(P0007705), patient 9 (P0007706), patient 10 (P0007707), and patient 15 (P0007703) 
into Phenome Central.  
 
Targeted Lipidomics Profiling 
Briefly, cells were harvested using trypsin, and cell pellets contained 3·5 million cells. 
50 mg muscle biopsy was snap frozen and stored at -80 °C until extraction. The 
zebrafish samples consisted of a pool of 5 zebrafish larvae (5 dpf) per experimental 
point (n=4) per condition. Lipidomics experiments were performed at Biocrates Life 
Science AG, as follows:  Fibroblast cells were lysed by freeze-thaw cycles and 
metabolites were extracted with 60 μl ice-cold methanol. Zebrafish larvae were 
homogenized using Precellys and metabolites were extracted with 60 μl ice-cold 
methanol. For measuring metabolite concentrations from muscle tissue, the samples 
were first weighed and then homogenized using Precellys in methanol. Samples were 
centrifuged and the supernatant was used for further analysis. Ceramides, 
dihydroceramides, and 2-hydroxyacyl ceramides were quantitatively analyzed by high-
throughput FIA-ESI-MS/MS. The reported lipid annotation represents a sum signal of 
all isobaric lipids with the same molecular weight (±0.5 Da range) within the same lipid 
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class. Multiple reaction monitoring (MRM) detection in positive and negative mode was 
performed using a SCIEX 4000 QTRAP® (SCIEX, Darmstadt, Germany) instrument. 
Sample preparation of 20 μL sample volume was followed by a MeOH/CHCl3-
liquid/liquid-extraction protocol. In addition to five internal standards to compensate for 
matrix effects, 43 external standards were used for a multi-point calibration.The 
quantitative data analysis was performed with our in-house software 
MetIDQ™ enabling isotopic correction. We declare that all pre-analytical and analytical 
procedures were performed, documented and reviewed according to our ISO 9001:2008 
certified in-house quality management rules and guidelines. 
 
 
Zebrafish strains 
Zebrafish embryos were obtained by mating of adult fish using standard methods. All 
fish strains were maintained individually as inbred lines. Wild type zebrafish strain was 
AB/Tu (RRID: ZIRC_ZL1/RRID: ZIRC_ZL57), and Tg(mbp:egfp) transgenic zebrafish 
was generated as described (27), in order to visualize myelinating oligodendrocytes in 
living zebrafish. Embryos were reared at 28·5 °C until processing for analyses at 
desired stages. 
In situ hybridization and immunolabeling 
Whole-mount in situ hybridization (ISH) was performed with standard protocols, as 
described previously (51). Embryos were fixed in 4% PFA, cryoprotected in 30% 
sucrose, and embedded in OCT. Blocks were frozen to improve tissue preservation, and 
then 10 µm sections were cut on a LeicaCM1510-1 cryostat (Leica). Hybridization was 
performed at 65°C with digoxigenin-labelled RNA probes. The antisense digoxigenin 
labelled RNA probe for zebrafish degs1  (ENSDART00000013007.5) was generated by 
in vitro transcription of an amplicon   from exon 1 (primers, forward 5’-ATG GGG 
AAC CGC GTG GCG CG -3’; reverse, 5’-TCA CTC CTG CTT GAC GTC TC -3’). 
Following purification, the fragment was cloned into a pBluescript dual promoter vector 
and was sequenced to confirm identity. The construct was linearized with BamHI, and 
digoxigenin-labelled antisense mRNA probe was generated by T3 in vitro transcription 
(DIG-RNA labelling kit, Roche 11-175-025-910). No signal was detected using the 
sense probe. 
For GFP immunolabeling, staged embryos were fixed in 4 % paraformaldehyde (PFA) 
at room temperature for 20 min, washed in 0·1 % Tween 20/PBS, and incubated 
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overnight at 4 °C with anti-GFP primary antibody (GFP102; 1:500; Aves Labs) in 
blocking solution followed by secondary antibodies conjugated with Alexa Fluor 488. 
Sections were then washed three times in 1X PBS and mounted in Fluoromount 
(Sigma). Cryostat sections were imaged on a Nikon ECLIPSE 80i fluorescence 
microscope. ISH and fluorescent images were processed using ImageJ (National 
Institutes of Health, Bethesda, MD). Confocal images were acquired using a Leica TCS 
SL laser scanning confocal spectral microscope (Leica Microsystems Heidelberg 
GmbH, Mannheim, Germany). Calculation of the number of MBP + cells was 
performed using plugins in ImageJ software. We imaged a fixed area in the spinal cord 
(dotted box in Figure 5H). MBP+ cells (myelinating oligodendrocytes) were counted in 
the dorsal spinal cord of 4·5 dpf larvae. 
 
Antisense morpholino injections 
For morpholino knockdowns, embryos were injected with splice-blocking (sb) 
morpholino oligomers (MOs) obtained from GeneTools LLC (Philomath, OR). MO-
degs1, 5´-GCT GAA TAA CTG CTC TCA CCA TTG G-3´ was designed as 
complementary to the genomic sequence flanking the exon 2-intron 2 boundary. Briefly, 
1 nl of 5 ng/nl or 10 ng/nl MO-control and MO-DEGS1 were injected into the yolk of 
one-cell stage embryos. After injection embryos were incubated at 28·5ºC until the 
desired stage was reached. Injected embryos and uninjected clutch-mate controls were 
analyzed from 0 - 5 days post-fertilization (dpf). Every day dead larvae were removed 
and the fraction of surviving larvae was recorded till 5 dpf. In order to verify the 
efficiency of the morpholinos, RNA from uninjected, control MO and MO-DEGS1 
injected larvae was extracted with Trizol (Thermo Fisher), and reverse transcription was 
performed with first-strand cDNA synthesis with the QuantiTect Reverse Transcription 
kit (Qiagen). The targeted region of degs1 was PCR-amplified using primers 
complementary to sites in flanking exons located in exon 2 (5´- GGC TCT CTG AAC 
CTG CTG AC -3´) and exon 3 (5´CTT GAC GTC TCC GAC CAG TT-3´), 
respectively using standard PCR conditions (Ta: 60 °C), and migrated by 
electrophoresis on a 1 % agarose gel; bands were excised, gel purified using QIAquick 
gel extraction kit (Qiagen) and resulting clones were Sanger sequenced to confirm 
aberrant splicing events induced by the MO (Supplementary Figure 4G-I). The standard 
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MO-control against β-globin was also obtained from GeneTools (5′-CCT CTT ACC 
TCA GTT ACA ATT TAT A-3′) was used as negative control.   
 
Larval Locomotor Behavior Assay 
By 5 dpf, zebrafish larvae perform spontaneous swimming and their visual system is 
fully developed. Uninjected, MO control and MO-DEGS1 120 hpf (hours post 
fertilization) larvae were transferred to individual wells of 96-well plate with 150 µl 
fresh fish water and allowed to acclimate for a few hours. The zebrafish larvae 
behaviour is tracked and analysed by the EthoVision XT software and the DanioVision 
device from Noldus Information Technologies, Wageningen, The Netherlands. This 
closed system consists of a camera placed above a chamber with circulating water and a 
temperature sensor that is set at 28·5 ºC. Individualized larvae in a 96-wells plate are 
placed in the chamber, which can provide different stimuli (light/dark environment, 
tapping, sound) controlled by the software. Prior to each experiment, larvae were left 
for 10 minutes in dark for acclimation, then predetermined series of alternating dark and 
light environment are presented to the larvae. The natural locomotor behaviour of 
zebrafish larvae is characterized by high activity in darkness and immobility in light 
environments. The final 25 min long experimental protocol is divided in 5 min period of 
darkness, and then two times repeated cycle of 5 min of bright light followed by 5 min 
of darkness. During the behavioural trial the total distance moved by every larva is 
measured. We obtained the distance moved and the mobility parameters from 
EthoVision tracking program analysis, and baseline parameters were subtracted out 
before. All locomotor assays were performed at 1pm onwards to ensure steady activity 
of zebrafish (52). After observations, all subjects were euthanized with a lethal 
concentration of MS-222 Tricaine (ethyl-3-aminobenzoate methane-sulfonate salt; 
Sigma). Swimming behaviour after drug treatment was performed by adding FTY720 to 
standard fish water to the final concentration of 3·3, 1·0, 0·3 ng/µl. DMSO was used as 
vehicle. MO control and MO-DEGS1 embryos (0 hpf) were treated with FTY720 till 
120 hpf and behavior assay was performed as described above. All measures were 
averaged across larvae within each condition (n = 20 larvae/condition) and reported as 
population means ± SD.  
 
Statistical analysis 
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All experiments were repeated at least 3 times with consistent results. All cell culture 
data were from biologic triplicates, unless otherwise indicated. Statistical analysis was 
performed with two-tailed unpaired Student’s t test (∗P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 
0.001), for comparison of 2 groups, and ANOVA followed by Tukey’s post hoc test for 
multiple comparisons (∗P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001) after verifying normality. 
Statistical analyses were performed using the GraphPad Prism 7.0 program. 
 
Study approval 
Human study: 
Human genetic studies conducted in research laboratories were approved by local ethics 
committees from participating centers (Barcelona, Spain (IDIBELL: PR076/14); Paris, 
France (INSERM U1163: 2015-03-03/DC 2014-2272; LEUKOFRANCE: CPP AU788; 
CNIL 1406552; AFSSAPS B90298-60); California, US (University of California, San 
Diego: IRB 140028), (Peking, China (Peking University First Hospital: [2005]004), 
Rochester, US (Mayo Clinic: IRB 12-009346), Baltimore, US (Johns Hopkins School of 
Medicine: NA_00045758); Hamilton, Canada; Ahvaz, Iran (Shahid Chamran University 
of Ahvaz: EE/97.24.3 17654/scu.ac.ir). Parental (or legal guardian) written informed 
consent was obtained for all affected children. Written informed consent was provided 
for the video appearing in supplementary data.  
 
Zebrafish study: 
All protocols used have been approved by the Institutional Animal Care and Use Ethic 
Committee (PRBB–IACUEC) and implemented according to national and European 
regulations. All experiments were carried out in accordance with the principles of the 
3Rs. 
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Figure legends 
 
Figure. 1. Scheme depicting enzyme defects associated with neurological disorders 
in the sphingolipid metabolism pathway, and Fingolimod (FTY720) action. Serine 
palmitoyltransferase (SPT) catalyzes the initial reaction of the de novo sphingolipid 
pathway. Dihydrosphingosine is produced after an intermediate step regulated by 3-
keto-dihydrosphingosine reductase (KDS), which is then followed by acylation by 
ceramide synthase (CerS) to produce dihydroceramide. The final reaction is the addition 
of a double bond by dihydroceramide desaturase DEGS1 to form ceramide. Ceramide is 
metabolized by ceramidase (CDse) to generate sphingosine, which in turn produces 
sphingosine 1-phosphate through phosphorylation by sphingosine kinase-1 and 
sphingosine kinase-2 (SphK1/2). Sphingosine 1-phosphate can be catabolized into 
hexadecenal and ethanolamine phosphate by sphingosine 1-phosphate lyase (S1PL). 
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Ceramide can be generated by the breakdown of sphingomyelin (SM) by acid (ASM) or 
neutral sphingomyelinases (NSM). Fingolimod (FTY720) has inhibitory effects on 
CerS. Enzyme (in bold) defects are indicated by solid bars across the blue arrows. The 
names of diseases are given (red box). SPT, serine palmitoyltransferase; KDS, 3-keto-
dihydrosphingosine reductase; CerS, ceramide synthase; DEGS1, dihydroceramide 
desaturase; HSN1, hereditary sensory neuropathy type I; MLD, metachromatic 
leukodystrophy; PD, Parkinson disease; GalCer, galactosylceramide; Sap, saposin. 
 
 
Figure 2. Schematic representation of human DEGS1 (NP_003667.1) and its 
functional domains with variants identified in patients. (A) DEGS1 has 323 amino 
acids. Numbers under the protein line indicate the boundaries of each domain. The lipid 
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DES domain (red) of DEGS1 comprises amino acids 6-42. The histidine domain 
(orange) of DEGS1 comprises amino acids 89-93, 128-132, and 259-263. The 
transmembrane domain (green) of DEGS1 comprises amino acids 43-62, 68-92, 104-
122, 150-172, 184-202, and 210-231. The fatty acid desaturase (FAD) domain covers 
amino acids 64-293. Multiple protein sequence alignment of DEGS1 orthologs show 
conservation of missense mutations detected in cases (bottom). (B) Schematic of the 
human DEGS1 locus which consists of three exons. The alignment was performed from 
different species is shown (bottom). The lipid DES, transmembrane and histidine 
domain are indicated by red, green and orange shading respectively. The alignment was 
performed with ClustalW using the following RefSeq numbers: NP_003667.1, Homo 
sapiens; NP_031879.1, Mus musculus; NP_445775.2, Rattus norvegicus; 
NP_001007485.1, Xenopus tropicalis; NP_997865.1, Danio rerio; NP_476594.1, 
Drosophila melanogaster; NP_493549.1, Caenorhabditis elegans. 
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Figure 3. Brain MRIs according to clinical severity and follow up.  
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(A) MRIs of patients with distinct clinical severity at the age of 6 years. Patient 7 (Top 
row) shows the mildest presentation with walking acquisition and spastic paraplegia. In 
FLAIR sequences, mild hyperintensities of the periventricular white matter (WM), with 
normal CC and internal capsule. In T1 sagittal, normal cerebellum and CC. Patient 9 
(low row) was able to hold the head but develop dystonia and spasticity with failure to 
thrive (-4SD). Despite this severe clinical presentation, the FLAIR sequences show an 
abnormal hypersignal of the white matter only in the periventricular and deep regions 
that are atrophic. The CC and the cerebellar vermis are atrophic.  
(B) Sequencial MRIs of patient 16. At 6 months all the WM structures including the 
cerebellum, the brainstem and the CC appear unmyelinated. The CC is thin on the T1 
sagittal section. A progression in the myelination has occurred at 2.5 y of age but the 
posterior part of the internal capsules is not myelinated, with periventricular 
hypersignals and an isosignal of the deep and subcortical WM and atrophic thalami. At 
4 years of age the internal capsules, the deep and subcortical WM show normal 
myelinated signal whereas the thalami appeared in hypersignal and atrophic, as well as 
the cerebellar vermis. 
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Figure 4. Dihydroceramides and ceramides imbalance in human patient 
fibroblasts (P4, P7, P9) and muscle (P3). (A) Ceramides (Cer), dihydroceramides 
(DhCer), and the ratios DhCer/Cer in human controls (n=9) and patient fibroblasts 
(n=3)+ and (B) in human controls (n=5) and patient muscle (n=1). Data are represented 
as percentage of total ceramides and dihydroceramides. (C) Intracellular ROS was 
quantified using the H2DCFDA probe in patient fibroblasts (patients 4, 7 and 9) and 
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controls (n=5) at a basal level+ (D) Exogenous DhCer (C18:0) treatment (20 µM, 6h) 
was applied to control and patient’s fibroblasts. Antimycin was used as positive control 
for ROS generation++. The fibroblasts results are from three independent experiments 
and they have been performed in triplicate. Data are shown as the means ± SD * 
p<0·05; ** p<0·01; *** p<0·001 after one-way ANOVA+ or two-way ANOVA++ test 
followed by Tukey’s post hoc test.  
 
Figure 5. Impact of Degs1 knockdown in Danio rerio larvae 
(A) Ceramides (Cer), dihydroceramides (DhCer), and the ratios DhCer/Cer in zebrafish 
MO-control and MO-DEGS1, n=4/condition (5 larvae per tube/condition), at 5 dpf+. 
Data are represented as percentage of total ceramides and dihydroceramides. (B) 
Representative images of the normal (blue), mild (purple), and severe (orange) 
phenotypes observed in the control and MO-DEGS1 injected groups. Scale bar: 10 μm. 
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(C) Quantification at 5 dpf of the percentage of normal, mild, and severe phenotype 
groups obtained. Values are the percentage ± SD of the three independent experiments 
with n = 50 animals per group per experiments. (D) Examples of digital tracks of 10 
single larvae of each condition shown in red. (E) Scatter plot displaying the total 
movement distance by different larvae (uninjected larvae (n=20): 1564·4 mm ± 321·6, 
MO-control (n=30): 1146·6 mm ± 255·2, MO-DEGS1 (n=33): 28·3 mm ± 24·5)++. (F-
H) Dorsal views of larvae injected with control and MO-DEGS1, and (F’-H’) inserts of 
boxed areas at 4·5 dpf. Scale bar: 100 μm. White arrows indicate MBP+ cells 
(myelinating oligodendrocytes). (I) Illustration of the tg(mbp:EGFP) larvae. (J) Scatter 
plot displaying the number of MBP+ in the dorsal spinal cord of 4·5 dpf larvae (MO-
control: n=30, MO-DEGS1: n=28, MO-DEGS1+1 ng/µl FTY720: n=19)++. Data are 
shown as the means ± SD; * p<0·05; ** p<0·01; *** p<0·001 after two-tailed unpaired 
Student’s t test+ or one-way ANOVA++ test followed by Tukey’s post hoc test. 
 
Figure 6. FTY720 ameliorates locomotor, biochemical and cellular phenotype in 
MO-DEGS1 larvae and lowers ROS levels in patient’s fibroblasts. (A) MO-DEGS1 
larvae were treated for 120 h with fingolimod (FTY720) at 0·3, 1·0 and 3·3 ng/µl. 
Digital tracks of larvae are shown in red. (B) Scatter plot (n=20 by condition) showing 
total movement distance (mm) upon FTY720 treatment++. Total movement distance 
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(mm) traveled by MO control (veh. 1268·2 mm ± 402·9); (FTY720, 1230 mm ± 365·2); 
compared to MO-DEGS1 (veh. 44·6 mm ± 39·2) and the different treatment doses 
(FTY720 3.3 ng/µl, 542·3 mm ± 238·8; FTY720 1ng/µl, 615·3 mm ± 330·8; FTY720 
0.3ng/µl, 670·3 mm ± 476·6). (C) Ceramides (Cer), dihydroceramides (DhCer), and the 
ratios DhCer/Cer in zebrafish MO-control and MO-DEGS1 treated with 1 ng/µl of 
FTY720 (n=4 (5 larvae per tube/condition) larvae/condition at 5 dpf ++). Data are 
represented as percentage of total ceramides and dihydroceramides. The results are from 
three independent experiments. (D) Intracellular ROS is partially normalized by 
FTY720 in patient fibroblasts++ (n=3) compared to controls (n=3). Data are shown as 
the means ± SD; * p<0·05; ** p<0·01; *** p<0·001 after one-way+ or two-way++ 
ANOVA test followed by Tukey’s post hoc test.  
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Family  Family 1 Family 2 Family 3 Family 4 Family 5 
Mutations c.395A>G: p.(His132Arg) 
c.397C>T/752dupT: 
p.(Arg133Trp)/ 
(Leu251Phefs*10) 
 c.341_342delTT/764A>G 
p.(Leu114Profs*11)/(Asn255Ser) 
 c.604delT 
 p.(Tyr202Thrfs*8) c.764A>G p.(Asn255Ser)  
Ethnicity Pakistani European/Caucasian European Caucasian Moroccan Moroccan 
Consanguinity yes no no no yes 
Family members 2 affected siblings 5 unaffected siblings 2 affected siblings 3 unaffected siblings 2 affected siblings 
Patient number Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 
Sex M M F F M F M M 
Death (age) no yes (7y) no no no yes (4 y) no no 
Age at last exam 6 y 7 y 9 y 9 y 6 y 4 y 13 y 9 y 
Age of onset (months) 2 0.5 12 6 6 1 24 24 
Term 34 WG 35 WG  38 WG 38 WG 39 WG 38 WG 39 WG 38 WG 
Birth WT; HT; OFC 2710g; 47cm; 37cm 
2400 g; 46 cm;35 
cm  4025 g; na; na  3883 g; 55,9 cm; na 4054 g; na; na 3200 g; 48.3 cm; na  3.115g; 50 cm;35 cm 
3.600 g; 49 cm; 
35 cm 
Motor acquisitions (age) none none sit unassisted (6m)        standing (9m) 
hold head; sit with 
support 
hold head; sit with 
support none 
walking without support 
short distance (2 y) 
walking with 
support (2 y) 
Motor developmental score 
(MDS) 0 0 2 1 1 0 4 3 
language acquisitions(age) none none simple sentences few words (1y) none 2 words associated sentences (5y) , simple reading sentences 
Regression (age) no no 1 y no no no 10 y no 
Neurological signs ax/limb dys; sp ax/limb dys; sp limb dys;sp; dysarthria limb dys; sp limb dys; sp ax dys sp; dysmetria  sp; dysmetria; dysarthria 
Eyes abnormalities 
slow pendular 
ocular 
movements; 
optic atrophy 
slow pendular 
ocular movements anisocoria  
Nystagmus and abnormal 
saccades. Mild optic 
atrophy 
none nystagmus(1m) then no fixation none none 
Acquired microcephalia (SD) no (-2) yes (-3) no (0) no (0) no (0) no (0) no (0) no (0) 
Failure to thrive (SD Weight; 
SD Height) yes (-4 W, -4 H) yes (-4 W, -4 H) yes (-2 W; -4H) yes (-4 W; -4 H) yes (-4 W; -4 H) na no (+1 W; +1 H) no (-1 W; -1 H) 
Gastrostomia yes (2 y; no gain) yes (4 y; no gain) Formula fed yes (2y gain) yes(4 y few gain) no no no 
Seizures (onset age) none none Partial complex and clonic 
clonic tonic severe (22m) 
status epilepticus. Stop 
Ketogenic diet (5y)  
clonic tonic  (2y). Stop 
ketogenic diet (2y) myoclonic  none partial complexes 
Other signs none Died suddenly of unrecognized cause Hip dysplasia 
Premature pubarche 
Kyphosis and scoliosis  Kyphosis and scoliosis none none none 
Abnormal nerve conduction 
velocities (<35m/s) yes (3y) yes (6y) no (8y) na na na na no (8 y) 
Long latencies of central 
conductions (>+2DS) na na na na na na na BAEP; SEP 
Table 1. Clinical description of family 1 to 5 (BAEP: Brain stem auditory potentials; VEP: visuel evoked potentials; SEP: Somatosensory evoked 
potentials; W: weight; H: height; OFC: occipitofrontal circumference; dys: dystonia; sp: spasticity; y: year; m month; nl: normal; na: not available; 
motor development score (0: no acquisition; 1 hold the head; 2 sit position without support; 3 walk with support; 4 walk unaided)).  
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Family  Family 6 Family 7 Family 8 Family 9 Family 10 Family 11 Family 12 Family13 
Mutations c.337A>G p.(Asn113Asp ) 
c.337A>G          
p.(Asn113Asp) c.320G>A p.(Trp107*) 
c.565A>G 
/764A>G 
p.(Asn189Asp)/As
n255Ser) 
c.852_855del p.(Tyr284*)
c.110T>C/878G>
A p.(Met37Thr)/ 
(Trp293*) 
c.320G>A    
p.(Trp107*) 
c.517C>T, 
p.(Arg173*) 
Ethnicity Algerian Algerian Egyptian Indian European Caucasian Chinese Egyptian Iranian-Lor 
Consanguinity yes yes yes yes (4th generation) no no yes yes 
Family members 1 unaffected sibling 
2 affected siblings 
died <14 y, 2 
healthy siblings 
3 affected siblings 1 unaffected sibling 2 affected siblings 1 unaffected sibling no sibling no sibling 
Patient number Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient14 Patient 15 Patient 16 Patient 17 Patient18 Patient19 
Sex F M F M M M M M F F M 
Death (age) no no yes (5 y) yes (2.5 y) no no no no no no no 
Age at last exam 9 y 20 y 5 y 2.5 y 4 y 18 y 1 y 4 y 5 y 7.5 y 10y 
Age of onset (months) 1 1 1 1 1 4 4 5 4 1 3 
Term 37WG 40 WG 39 WG 38 WG 38 WG 39 WG 39 WG 40 WG 39 WG 38 WG 39 WG 
Birth WT; HT; OFC 3280 g; 49 cm; 34cm 3700g; 50cm; 36 cm 
3500g; 48cm; 
34.5cm 
3200g; 50cm; 
35.5cm 
3100g; 
51cm; 35cm 3300 g; 55 cm. na 
3401g; na; 
na 
3515g; na; 
na 3300 g; na; na 
2500g; 
48cm; 34cm 2950g; 44cm; 34 cm 
Motor acquisitions 
(age) 
hold head; sit with 
support 
hold head; sit with 
support none none none sit unassisted (5 m) 
hold head; 
sit with 
support 
hold head; 
sit with 
support 
hold head none none 
MDS 1 1 0 0 0 2 1 1 1 0 0 
language 
acquisitions(age) none none none none none single words (2y) none none none none none 
Regression (age) no no no no no 6m no no no no no 
Neurological signs limb dys; sp ax/limb dys; sp limb dys; sp limb dys; sp limb dys; sp choreoathetosis; sp sp sp sp sp dys; sp 
Eyes abnormalities 
nystagmus (1m), 1 
episode of tonic-upgaze 
like (8y), ERG nl 
nystagmus (1m)     
ERG nl 
nystagmus. (1m)   
ERG nl 
nystagmus.(1m  
ERG nl 
nystagmus(1
m) ERG nl nystagmus (4m) 
nystagmus 
(4m) 
nystagmus 
(5m) none 
nystagmus 
(1m) nystagmus 
Acquired 
microcephalia (SD) no (-2) no (-2) no (-2) no (-2) no (+1) na no (+1) no (+1) na yes (-4.8) yes (-4) 
Failure to thrive (SD 
Weight; SD Height) yes (-3,5 w; -4 H) yes (-5 W; -5 H) yes (-4 W; -4 H) yes (-4W; -4H)
no (-2 W; -
2H) yes (-6 W; -6 H) 
no (-1.W; 0 
H) 
no (-2 W; 
-1 H) no (-1 W; +2 H) 
yes (-3.5W; -
6H) yes (-4.5W; -3.5 H) 
Gastrostomia no yes (18y) Feeding diffculties 
Feeding 
diffculties 
Feeding 
diffculties yes (1 y) yes (1 y) yes (2.5 y) no no 
Feeding difficulties, 
Dysphagia 
Seizures (onset age) clonic tonic  (8m) with status epilepticus myoclonic  (2 y) 
partial and 
myoclonic (3y) 
toic, atonic (8 
m) tonic (2.5y) tonic clonic (5y) none 
tonic 
clonic none Febrile (4y). none 
Other signs 
gingival hypertrophy , 
scoliosis & hip 
dislocation > 4.5 years 
of age. 
gingival 
hypertrophy. 
Severe scoliosis 
and joint 
contractions 
Hemorrhagic 
infarction at the 
age of 3, coma 
for 10 days, 
severe 
deterioration 
Died suddenly 
of 
unrecognized 
cause 
none joints contractures 
Skin 
hypopigment
ation. 
scoliosis. 
Skin 
hypopigm
entation. 
none none 
Kyphosis,Coarse 
face, Hirsutism, 
Bruxism 
Abnormal nerve 
conduction velocities  no (1 y;) yes (2y) yes (3y) no (4y) na no no (17y) no (1y) no (4y) no (4y) yes (6y) na 
Long latencies of 
central conductions  VEP; BAEP VEP; BAEP VEP VEP VEP na BAEP na na na na 
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Table 2. Clinical description of family 6 to 13 (BAEP: Brain stem auditory potentials; VEP: visuel evoked potentials; SEP: Somatosensory evoked 
potentials; W: weight; H: height; OFC: occipitofrontal circumference; dys: dystonia; sp: spasticity; y: year; m month; nl: normal; na: not available; 
motor development score (0: no acquisition; 1 hold the head; 2 sit position without support; 3 walk with support; 4 walk unaided)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
Patient number Patient 1 Patient 2 
Patient 
3 
Patient 
4 
Patient 
5 
Patient 
6 
Patient 
7 
Patient 
8 
Patient 
9 
Patient 
10 
Patient 
11  
Patient 
12  
Patient 
13  
Patient 
14 Patient 15
Patient 
16 
Patient 
17 
Patient 
18 Patient19 
MRI (age of 
acquisition) 5m 6y 8 y 2y; 4 y 2 y 1 y 6 y 8 y 
8m; 2.5 
y; 6 y 2 y; 12 y 2 y; 3 y 1 y 10 m 17 y 11m 
6m; 2.5 
y; 4y 
8m; 
16m 6 y 10y 
hypomyelination 
according to age 
on the last MRI 
                                      
cerebellum + no no no no + no no + + no + + no no no no na No 
brainstem no no no no no no no no + no no + no no no no no na No 
cc + + no no no no no no no no no no + no +/- no + na +/- 
internal capsules no no no no no + no no no + no no + no no no + na no 
periventricular WM no + + + + + + + + + + + + + + + + na + 
deep WM no + no + +/- + no no + + + + + no + + + na + 
subcortical WM no +/- no no no no no no no no no + no no no no +/- na no 
myelin progression na na na yes na na na na yes yes yes na na na na yes yes na na 
Basal ganglia 
abnormalities 
hyper 
T2 
thalami 
hypo T2 
pallidi; 
atrophy 
hyper T2 
thalami  
no 
atrophy 
hyper 
T2 
thalami 
atrophy 
hyper 
T2 
thalami 
no no no 
atrophy 
hyper 
T2 
thalami 
atrophy 
hyper 
T2 
thalami  
no no no 
atrophy 
hyper 
T2 
thalami 
hyper T2 
dentate 
nucleus , 
hyper T2 
thalami 
mild 
atrophy 
hyper 
Flair 
thalami 
atrophy 
hyper 
T2 
thalami 
na 
hypo T2 
pallidi; 
atrophy 
hyper T2 
thalami 
other none 
hypo T1 in 
the 
occipital 
deep 
WM/subc
ortical 
junction 
none none none none 
enlargm
ent WR 
spaces 
enlargm
ent WR 
spaces.   
spinal 
cord 
normal 
none 
Hypo 
T1 in 
the 
occipital 
deep 
WM/ 
occipital 
hemorag
ic 
infarctio
n at 3 
none none none none no no na no 
calcifications (CT 
scan ) no 
yes 
(periventri
cular) 
na na na na na na no no 
yes 
(cerebell
um) 
yes 
(cerebell
um) 
yes 
(cerebell
um) 
na no no na na na 
atrophy                                       
cerebellum no ++ no no no no no no + ++ + + no + no + no na ++ 
ventricule dilatation + + no no no + no no no + + no no no no + no na + 
cortical no no no no no no no no no 
++ 
(frontal 
and 
sylvian 
fissures) 
+ 
+ 
(sylvian 
fissures)
+ 
(sylvian 
fissures)
no no no no na 
++ 
(frontal 
and 
sylvian 
fissures) 
CC no ++ no 
+ 
(spleniu
m) 
+ 
(spleniu
m) 
+ no no + ++ + + + + + + 
+ 
(spleniu
m) 
na ++ 
MRS         na na na na   na na na na na na   na na na 
NAA nl low  nl low         low             low      
Choline high high nl high         nl             nl      
lactates - + - -         +/-             -      
41 
Table 3. MRI description (WM: white matter; + present; WR: Wirchow Robin; y: year; m month; nl: normal; na: not available). 
